$TCRR News
Last published 3y ago
- 3y agoTCRRTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for
- 3y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 3y agoTCRRGlobal Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ DrugsPR NewswireDUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer- Competitive landscape,
- 3y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors,
- 3y agoTCRRTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumorsFollowing the expected Q2 2023 closing of the all-stock transaction, the combined
- 3y agoDSEYKBALRADITCRRMoore Kuehn Encourages KBAL, DSEY, RADI, and TCRR Investors to Contact Law FirmPR NewswireNEW YORK, March 10, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoBTERADITCRRVBLTMoore Kuehn Encourages VBLT, RADI, TCRR, and BTE Investors to Contact Law FirmGlobeNewswireNEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoADAPTCRRAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsGlobeNewswireCompelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity
- 3y agoTCRRTCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023GlobeNewswireCAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 3y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 3y agoTCRRTCR² Therapeutics Announces Pipeline Priorities for 2023GlobeNewswiregavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical
- 3y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 3y agoTCRRTCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 4y agoTCRRTCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors,
- 4y agoTCRRTCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerGlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committ
- 4y agoTCRRgavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and MesotheliomaGlobeNewswire- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consist
- 4y agoTCRRTCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsGlobeNewswireCAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans
- 4y agoTCRRTCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitGlobeNewswireCAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will pa
- 4y agoTCRRTCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee o
- 4y agoTCRRTCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp CAMBRIDGE,
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committ
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committ
- 4y agoTCRRTCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial OfficerGlobeNewswireCAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on May 31, 2022 (th
- 4y agoTCRRTCR² Therapeutics to Participate in Two Upcoming Conferences in JuneGlobeNewswireCAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will par
- 4y agoTCRRTCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in July 2022- Updates anticipated in the s
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on April 29, 2022 (t
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on March 31, 2022
- 4y agoAVGRDPROENSVHOFV+1Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics?PR NewswireNEW YORK, March 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DPRO, ENSV, AVGR, HOFV, and TCRR.
- 4y agoTCRRTCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial result
- 4y agoTCRRTCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022GlobeNewswireCAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poste
- 4y agoTCRRTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on February 28, 20
- 4y agoTCRRTCR² Therapeutics to Present at the SVB Leerink Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management w
- 4y agoTCRRTCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy OfficerGlobeNewswireCAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosem
- 4y agoTCRRTCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated MilestonesGlobeNewswire- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022- Sele
- 4y agoTCRRTCR² Therapeutics to Present at the J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/ TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors
- 4y agoTCRRTCR² Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Me
- 4y agoTCRRTCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell TherapiesGlobeNewswireCAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies, a biot
- 5y agoBMYTCRRTCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results
- 5y agoTCRRTCR² Therapeutics Announces Expansion of U.S. Manufacturing CapacityGlobeNewswire- Second clean room at ElevateBio BaseCamp will expand cGMP capacity for clinical trials in 2022 - Future network to focus on TCR2 manufacturing center of excellence in Rockville, MD - Strategy optimizes efficiencies and simplifies regulatory pathw
- 5y agoBMYTCRRTCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid TumorsGlobeNewswireCAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced a clinical trial collabo
- 5y agoTCRRTCR² Therapeutics Reviews Pipeline and Strategy at R&D DayGlobeNewswire- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of plat
- 5y agoTCRRTCR² Therapeutics to Host R&D Day on October 20, 2021GlobeNewswireCAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&
- 5y agoTCRRTCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & ImmunotherapyGlobeNewswireCAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of n
- 5y agoTCRRTCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid TumorsGlobeNewswire- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall response rate (ORR) 31% in patients infused with ga
- 5y agoTCRRTCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid TumorsGlobeNewswireCAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a
- 5y agoTCRRTCR² Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Finan
- 5y agoTCRRTCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of CholangiocarcinomaGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug A